Ling-Mei Wang,
President and COO,
Steminent Biotherapeutics
Ling-Mei Wang is the President and COO of Steminent Biotherapeutics in Taiwan, the leading Phase-2 stage company dedicated to the development of novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs. Steminent utilizes its proprietary Stemchymal® platform to manufacture standardized stem cell products of the highest quality for research and clinical development in neurodegenerative, liver, and other therapeutic areas. To further advance its technologies, the company is taking a distributed R&D model by closely collaborating with researchers of UHN, Canada and other medical institutes.
Ling-Mei has over 25 years of R&D and management experiences in a wide spectrum of research area including cancer, human genomics and regenerative medicine in both academic and industrial sectors. Prior to joining SBI, Ling-Mei held a list of managerial positions including the Vice-President of CHO Pharma Inc., the COO and the CTO of Taiwan Supra Integration and Incubation Center (Si2C), the Deputy General Director and the CTO at Biomedical Technology and Device Research Laboratories of Industrial Technology Research Institute (ITRI), the Associate Principal Investigator at National Health Research Institute (NHRI), and the Director of R&D at Vita Genomics. Ling-Mei received her Ph.D. degree from University of Texas Health Science Center at San Antonio, USA, and was a researcher at National Cancer Institute in USA for 10 years before returning to Taiwan.
Therapeutic Considerations of Mesenchymal Stromal Cells
Monday, 11 November 2019 at 14:40
Add to Calendar ▼2019-11-11 14:40:002019-11-11 15:40:00Europe/LondonTherapeutic Considerations of Mesenchymal Stromal CellsCell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com
Mesenchymal Stromal Cells (MSCs), with its unique anti-inflammatory and immunomodulatory functions, have been widely considered as a viable drug agent for many unmet or underserved disease indications. Anyhow challenges remain before we can see more popularized clinical applications. Some critical dimensions include the high level of biological complexities, regulatory requirements, and manufacturing scale-up. This presentation will have an overview of some essential issues to be considered, along with suggested approaches in developing viable clinical use of MSCs. Steminent Biotherapeutics, with its proprietary allogenic stem cell technologies, will present some of the key findings of utilizing MSC-based treatments on Spinocerebellar Ataxia (SCA) and Acute Liver Failures (ALF), both are debilitating medical needs without effective options.
Add to Calendar ▼2019-11-11 00:00:002019-11-12 00:00:00Europe/LondonCell and Gene Therapy Asia 2019Cell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-11-11 14:40:002019-11-11 15:40:00Europe/LondonTherapeutic Considerations of Mesenchymal Stromal CellsCell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com
